Lisata Therapeutics (NASDAQ:LSTA) and Caribou Biosciences (NASDAQ:CRBU) Financial Analysis

Caribou Biosciences (NASDAQ:CRBU) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Profitability

This table compares Caribou Biosciences and Lisata Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%
Lisata Therapeutics	N/A	-116.08%	-90.55%

Analyst Ratings

This is a breakdown of current ratings and target prices for Caribou Biosciences and Lisata Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1	0	3	1	2.80
Lisata Therapeutics	1	2	0	0	1.67

Caribou Biosciences presently has a consensus price target of $7.75, suggesting a potential upside of 496.15%. Given Caribou Biosciences’ stronger consensus rating and higher possible upside, equities analysts plainly believe Caribou Biosciences is more favorable than Lisata Therapeutics.

Institutional & Insider Ownership

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Caribou Biosciences has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Valuation & Earnings

This table compares Caribou Biosciences and Lisata Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16 million	12.49	-$148.12 million	($1.08)	-1.20
Lisata Therapeutics	$170,000.00	82.68	-$16.59 million	($1.64)	-0.95

Lisata Therapeutics has lower revenue, but higher earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Caribou Biosciences beats Lisata Therapeutics on 10 of the 15 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.